Mineralys Therapeutics Shares Fall Following Executives' Stock Sale

MT Newswires Live11-15

Mineralys Therapeutics (MLYS) shares were down more than 10% in recent Friday trading following a series of stock sales by a number of company executives.

Filings with the US Securities and Exchange Commission Thursday showed that Chief Executive Officer Jon Congleton and Chief Financial Officer Adam Levy, along with directors Daphne Karydas and Alexander Gold, recently sold Mineralys shares in a number of transactions.

Congleton sold 200,000 shares, bringing his holdings down to 631,305 while Levy sold nearly 120,000 shares and now holds 19,396 shares following the transactions, according to the filings.

Price: 39.79, Change: -4.50, Percent Change: -10.16

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment